Bacteromic, part of the Warsaw Stock Exchange-listed Scope Fluidics Group, has established an international Clinical Advisory Board. This team of independent clinical experts will support the development of the Group’s most advanced project, the BACTEROMIC system. The Advisory Board, composed of specialists from the United Kingdom, Italy, and the United States, will assist Bacteromic in fine-tuning the system to meet clinical and market needs. This will provide significant support for the further development of diagnostic technologies and their commercialization in international markets.
The Clinical Advisory Board is a team of independent clinical experts who support Bacteromic in key scientific and business areas. Its members include recognized international clinical and market experts in clinical microbiology, representing leading clinical centers and possessing unique experience in aligning microbiological diagnostic products with market needs.
Stefan Riedel (United States) is a professor of pathology at Harvard Medical School and head of clinical microbiology laboratories at Beth Israel Deaconess Medical Center. He is a recognized authority in the fields of sepsis research and bacterial resistance. His deep understanding of laboratory practice and microbiological diagnostics provides him with extensive knowledge of best practices in connecting diagnostics with real clinical needs.
Stephen Kidd (United Kingdom) is a clinical scientist specializing in microbiology (including research on antibiotic resistance) and virology, with more than 23 years of experience in clinical diagnostics. He is currently affiliated, among others, with the Hampshire Hospitals NHS Foundation Trust, where he serves as Principal Clinical Scientist.
Tiziana Di Martino (Italy) is a physician and manager with over 20 years of experience in clinical practice, scientific research, and health economics. She also has extensive experience in the MedTech and IVD sectors.
Scott O’Brien (United States) is a manager with more than 25 years of experience in the global life sciences and diagnostics industry, covering areas such as R&D, marketing, commercialization, and international management, including positions at companies such as SpecificDx and GeneMark. Scott brings substantial experience in global product launches.
“We are very pleased to establish an international Clinical Advisory Board whose members will contribute unique clinical expertise and a business-oriented perspective to the development of our diagnostic technologies. Collaboration with distinguished experts from the United Kingdom, Italy, and the United States strengthens our scientific credibility and confirms the global nature of our activities. The results achieved so far by the BACTEROMIC system reinforce our conviction that the development path we have chosen is the right one, and with the support of the Advisory Board, we can pursue it with even greater confidence. The BACTEROMIC system is currently the most advanced project in the Scope Fluidics portfolio, and our cooperation with the Board marks an important step toward its commercialization and introduction to international markets,” said Prof. Piotr Garstecki, CEO of Scope Fluidics.
